CAC2 Webinar–The Blood-Brain Barrier: What If You Could Get Drugs Across?

In this January 2017  CAC2 All-Member webinar, we provided an opportunity to our members, associate members, student members, and supporting organizations to learn about emerging technology using ultrasound and microbubbles to deliver therapeutic agents across the blood-brain barrier.  Clay Larsen, President & CEO and Rhodemann Li, Founder, EVP Strategy & Finance, both of Vesselon, presented about their plans for this technology in the pediatric brain tumor population. The blood-brain barrier (BBB) is the body's natural defense mechanism to prevent toxins from entering the brain.  Unfortunately, it also prevents 99% of all therapeutic molecules from getting to their target to treat many diseases, [...] Read more

An Individualized Approach Requires Collaborative Efforts

By Vickie Buenger, President of Coalition Against Childhood Cancer The Coalition Against Childhood Cancer (CAC2) held its first pediatric cancer research conference entitled From Bench to Bedside and Beyond to connect childhood cancer advocates, research funders, clinicians, and scientists from academia and industry. A number of common themes emerged from the various investigators’ presentations. Clearly, most childhood cancers are different than adult cancers, and the relatively small numbers of patients present problems for researchers, sponsors, and others responsible for designing clinical trials. We must remember that these small clusters of patients represent our children. Presenters also agreed that despite progress [...] Read more

CAC2 Member Blog–Triage Cancer

By CAC2 Member Angie Giallourakis, Steve G. Cancer Research Fund TRIAGE CANCER: verb. \trē-ˈäzh,ˈkansər\ the assigning of priority order to projects on the basis of where time, funds, and other resources can be best used, are most needed, or are most likely to achieve success in navigating cancer survivorship issues. I was first introduced to Triage Cancer a few years ago at a Critical Mass: YA (young adult) Cancer Alliance conference where a speaker addressed attendees about Obamacare. It didn’t surprise me that shortly after the conference I began receiving some of the most noteworthy information about programs on cancer survivorship. […]

Read more

CAC2 Webinar–The Canine-Kid Connection

In this All-Member Webinar for November 2016, we provided an overview of the compelling case for studying and treating cancer in canine cancer patients – a model of spontaneously occurring disease - the underlying science, and its potential not only to help us better understand and treat pediatric cancer, but also to accelerate the pediatric cancer drug development process. CAC2 Member Ulrike Szalay of Canines -N-Kids explains:  "As we know too well, cancer is the #1 cause of disease-related death in children in most developed countries. At least 1 in 5 will die from their disease, while the vast majority [...] Read more

CAC2 Webinar–The Blue Ribbon Panel Report and Pediatric Cancer

Earlier this year, as part of Vice President Biden’s Cancer Moonshot initiative, the White House established a Blue Ribbon Panel of experts to report on the current challenges and opportunities facing cancer research. In this CAC2 Research Interest Group webinar for September1 2016, CAC2 welcomed Blue Ribbon Panel members Dr. Peter Adamson (Chair of the Children's Oncology Group) and David Arons (CEO of the National Brain Tumor Society) in a discussion of the panel’s recently issued report and its implications for pediatric cancer. https://youtu.be/QGlWWQrcBlo Read more

CAC2 Member Blog–Three Words I Heard from my Pediatric Oncologist that Still Haunt Me

By CAC2 Member Kayla Funk, Open Hands, Overflowing Hearts   The world stopped spinning for a moment. Time beyond the oncology clinic stood still. Though I knew he was right, I refused to believe my doctor and the words coming out of his mouth. “When neuroblastoma progresses through therapy, we are unable to cure it.” I listened, but I ignored him. I was 19 years old and had spent the last 15 months of my life going through gruesome treatments. The cancer should not have grown. “We will try to suppress your disease for as long as possible, but I don’t […]

Read more

CAC2 Member Blog–“Am I Going to Die?” Reflections of a Survivor

By CAC2 Individual Member Angela Lee I remember ‘that day’ like it was yesterday. The sun was shining on a beautiful spring day in Virginia as my mom and I sat quietly in a hospital room waiting for an oncologist to pay us a visit. I was admitted just days before for a series of lab work and tests that reduced me to feeling like a science project. Although I remember that day very clearly, it was 32 years ago that I heard “It’s a form of cancer” followed by my response “Am I going to die?’. On a beautiful [...] Read more

CAC2 Webinar–Basics of a Clinical Trial in Pediatrics: A Sponsor’s Perspective

In this All-Member and all-community webinar for August 2016, CAC2 welcomes Drs. Michael Trigg, Brigid Bradley-Garelik, and Greg Plautz from Bristol-Myers Squib, speaking on the clinical trial process. These three esteemed industry experts provided an overview of the clinical trial process, particularly from an industry-sponsored trial perspective and cover topics such as clinical trial designs, different required FDA phases of drug development, data monitoring committees, general principles of pediatric trials and special considerations of pediatric trials, industry obligations to pediatrics and personalized medicine. This presentation was not recorded. Read more

CAC2 Members Reflections on the National Cancer Moonshot Summit

By CAC2 Member David Frazer, National Pediatric Cancer Foundation “The Moonshot Summit was an event that gathered the principals within the oncology industry under the inspirational leadership of Vice President Biden.   In my opinion, all politics aside, Mr. Biden portrayed the type of leadership necessary to conduct systematic change to defeat cancer.  Historically, he has always been a champion for public health.   The summit was based on collaboration and change, and Mr. Biden facilitated an effective initiative to drive those focus topics. On June 29, the Vice President gathered 300 cancer experts and advocates to Howard University. Of the 14 advocates and foundations […]

Read more

CAC2 Webinar–Cavatica: The Promise of Big Data

In this CAC2 Research Interest Group webinar for July 2016, CAC2 welcomed host Dr. Adam Resnick of the Children's Hospital of Philadelphia, Dr. Javad Nazarian of Children's Nationwide Hospital, and CAC2 member Amanda Haddock (Dragon Masters Foundation) discussing the Cavatica platform and how it can bring pediatric cancer research in line with the adult initiatives. Dr. Reznick presented about Cavatica, an exciting new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric brain tumor genomics data.  Cavatica will, for the first time, allow doctors, researchers and data scientists unparalleled access to pediatric brain tumor genomic data paired with a [...] Read more